aspirin

Summary

Summary: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)

Top Publications

  1. pmc Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
    Colin Baigent
    CTSU, Oxford University, Oxford, UK
    Lancet 373:1849-60. 2009
  2. doi Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
    Peter M Rothwell
    Stroke Prevention Research Unit, Department of Clinical Neurology, University of Oxford, Oxford, UK
    Lancet 377:31-41. 2011
  3. pmc Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals
    Charles N Serhan
    Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Exp Med 196:1025-37. 2002
  4. ncbi Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
    Jonathan Mant
    Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
    Lancet 370:493-503. 2007
  5. ncbi Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials
    Peter M Rothwell
    Stroke Prevention Research Unit, Nuffield Department of Clinical Neuroscience, University of Oxford, UK
    Lancet 379:1602-12. 2012
  6. ncbi Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
    S Connolly
    Health Research Institute, Hamilton, ON, Canada
    Lancet 367:1903-12. 2006
  7. ncbi Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation
    Yee Ping Sun
    Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 282:9323-34. 2007
  8. pmc Aspirin intake and survival after breast cancer
    Michelle D Holmes
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 28:1467-72. 2010
  9. ncbi Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials
    Peter M Rothwell
    Stroke Prevention Research Unit, Nuffield Department of Clinical Neuroscience, University of Oxford, UK
    Lancet 379:1591-601. 2012
  10. ncbi Clopidogrel with or without omeprazole in coronary artery disease
    Deepak L Bhatt
    Veterans AffairsBoston Healthcare System, Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 363:1909-17. 2010

Detail Information

Publications340 found, 100 shown here

  1. pmc Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
    Colin Baigent
    CTSU, Oxford University, Oxford, UK
    Lancet 373:1849-60. 2009
    Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention.
  2. doi Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
    Peter M Rothwell
    Stroke Prevention Research Unit, Department of Clinical Neurology, University of Oxford, Oxford, UK
    Lancet 377:31-41. 2011
    Treatment with daily aspirin for 5 years or longer reduces subsequent risk of colorectal cancer...
  3. pmc Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals
    Charles N Serhan
    Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Exp Med 196:1025-37. 2002
    b>Aspirin (ASA) is unique among current therapies because it acetylates cyclooxygenase (COX)-2 enabling the biosynthesis of R-containing precursors of endogenous antiinflammatory mediators...
  4. ncbi Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
    Jonathan Mant
    Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
    Lancet 370:493-503. 2007
    ..We assessed whether warfarin reduced risk of major stroke, arterial embolism, or other intracranial haemorrhage compared with aspirin in elderly patients.
  5. ncbi Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials
    Peter M Rothwell
    Stroke Prevention Research Unit, Nuffield Department of Clinical Neuroscience, University of Oxford, UK
    Lancet 379:1602-12. 2012
    Daily aspirin reduces the long-term risk of death due to cancer...
  6. ncbi Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
    S Connolly
    Health Research Institute, Hamilton, ON, Canada
    Lancet 367:1903-12. 2006
    ..However, long-term monitoring is necessary and many patients cannot achieve optimum anticoagulation. We assessed whether clopidogrel plus aspirin was non-inferior to oral anticoagulation therapy for prevention of vascular events.
  7. ncbi Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation
    Yee Ping Sun
    Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 282:9323-34. 2007
    ..stereochemistry of the conjugated double bonds and chirality of alcohols present in resolvin D1 (RvD1) and its aspirin-triggered 17R epimer (AT-RvD1) with compounds prepared by total organic synthesis...
  8. pmc Aspirin intake and survival after breast cancer
    Michelle D Holmes
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 28:1467-72. 2010
    Animal and in vitro studies suggest that aspirin may inhibit breast cancer metastasis. We studied whether aspirin use among women with breast cancer decreased their risk of death from breast cancer.
  9. ncbi Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials
    Peter M Rothwell
    Stroke Prevention Research Unit, Nuffield Department of Clinical Neuroscience, University of Oxford, UK
    Lancet 379:1591-601. 2012
    Daily aspirin reduces the long-term incidence of some adenocarcinomas, but effects on mortality due to some cancers appear after only a few years, suggesting that it might also reduce growth or metastasis...
  10. ncbi Clopidogrel with or without omeprazole in coronary artery disease
    Deepak L Bhatt
    Veterans AffairsBoston Healthcare System, Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 363:1909-17. 2010
    ..Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel...
  11. pmc Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor
    Mauro Perretti
    1 Department of Biochemical Pharmacology, William Harvey Research Institute, Bart s and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London, UK 2 M P and N C contributed equally to this paper
    Nat Med 8:1296-302. 2002
    b>Aspirin (ASA) and dexamethasone (DEX) are widely used anti-inflammatory agents yet their mechanism(s) for blocking polymorphonuclear neutrophil (PMN) accumulation at sites of inflammation remains unclear...
  12. doi Aspirin and cancer risk: a quantitative review to 2011
    C Bosetti
    Department of Epidemiology, Istituto di Ricerche Farmacologiche, Mario Negri, Milan, Italy
    Ann Oncol 23:1403-15. 2012
    b>Aspirin has been associated to a reduced risk of colorectal and possibly of a few other common cancers.
  13. doi Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells
    Haider Raza
    Department of Biochemistry, Faculty of Medicine and Health Sciences, UAE University, POBox 17666, Al Ain, United Arab Emirates
    Eur J Pharmacol 668:15-24. 2011
    It is widely accepted that non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, reduce the risk of cancer...
  14. pmc Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
    Giorgia De Berardis
    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8 A, 66030 S Maria Imbaro, Italy
    BMJ 339:b4531. 2009
    To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease.
  15. pmc Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
    R E Langley
    MRC Clinical Trials Unit, London, UK
    Br J Cancer 105:1107-13. 2011
    b>Aspirin inhibits the enzyme cyclooxygenase (Cox), and there is a significant body of epidemiological evidence demonstrating that regular aspirin use is associated with a decreased incidence of developing cancer...
  16. pmc Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival
    Xiaoyun Liao
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 367:1596-606. 2012
    Regular use of aspirin after a diagnosis of colon cancer has been associated with a superior clinical outcome...
  17. pmc Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells
    Farhat V N Din
    Colon Cancer Genetics Group and Academic Coloproctology, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council Human Genetics Unit, Western General Hospital Edinburgh, United Kingdom
    Gastroenterology 142:1504-15.e3. 2012
    b>Aspirin reduces the incidence of and mortality from colorectal cancer (CRC) by unknown mechanisms. Cancer cells have defects in signaling via the mechanistic target of rapamycin (mTOR), which regulates proliferation...
  18. ncbi Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement
    Jack Cuzick
    Cancer Research UK Centre for Epidemiology, Mathematics, and Statistics, Queen Mary University of London, London UK
    Lancet Oncol 10:501-7. 2009
    Evidence clearly shows a chemopreventive effect for aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) on colorectal cancer and probably other cancer types; however, data on the risk-benefit profile for cancer prevention ..
  19. doi Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial
    Hisao Ogawa
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1 1 1 Honjo, Kumamoto City, 860 8556, Japan
    JAMA 300:2134-41. 2008
    Previous trials have investigated the effects of low-dose aspirin on primary prevention of cardiovascular events, but not in patients with type 2 diabetes.
  20. ncbi Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis
    Charles N Serhan
    Department of Anesthesiology, Perioperative and Pain Medicine, Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Prostaglandins Other Lipid Mediat 73:155-72. 2004
    ..b>Aspirin treatment impacts biosynthesis of these compounds and a related series by triggering endogenous formation of the ..
  21. ncbi Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators
    R G Hart
    Department of Medicine, University of Texas Health Science Center, San Antonio 78284, USA
    J Am Coll Cardiol 35:183-7. 2000
    ..This study was performed to characterize the risk of stroke in elderly patients with recurrent intermittent atrial fibrillation (AF)...
  22. pmc Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins
    Matthew Spite
    Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Circ Res 107:1170-84. 2010
    ..Here, we overview and update the biosynthesis and actions of proresolving lipid mediators, highlighting their diverse protective roles relevant to vascular systems and their relation to aspirin and statin therapies.
  23. doi Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
    Peter M Rothwell
    Stroke Prevention Research Unit, Department of Clinical Neurology, University of Oxford, Oxford, UK
    Lancet 376:1741-50. 2010
    High-dose aspirin (≥500 mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention. The long-term effectiveness of lower doses (75-300 mg daily) is unknown...
  24. ncbi Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials
    Annemijn M Algra
    Stroke Prevention Research Unit, University Department of Clinical Neurology, University of Oxford, Oxford, UK
    Lancet Oncol 13:518-27. 2012
    Long-term follow-up of randomised trials of aspirin in prevention of vascular events showed that daily aspirin reduced the incidence of colorectal cancer and several other cancers and reduced metastasis...
  25. doi Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma
    Jordi Roca-Ferrer
    Immunoallergia Respiratoria Clinica i Experimental, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    J Allergy Clin Immunol 128:66-72.e1. 2011
    Researchers have debated whether regulation of the COX enzymes (COX-1 and COX-2), which mediate production of prostaglandins (PGs), affects the pathogenesis of nasal polyps (NPs) and aspirin-intolerant asthma (AIA).
  26. doi Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
    Wiktor Kuliczkowski
    3rd Department of Cardiology, Silesian Center for Heart Diseases, Zabrze, Poland
    Eur Heart J 30:426-35. 2009
    ..The efficacy of acetylsalicylic acid (ASA, aspirin) and clopidogrel in decreasing the risk of adverse events in coronary heart disease patients has been well ..
  27. ncbi Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation
    Morten L Hansen
    Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65 2900, Hellerup, Copenhagen, Denmark
    Arch Intern Med 170:1433-41. 2010
    ..Patients with atrial fibrillation (AF) often require anticoagulation and platelet inhibition, but data are limited on the bleeding risk of combination therapy...
  28. ncbi A new combined test with flowcytometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs
    M L Sanz
    Department of Allergology and Clinical Immunology, University of Navarra, Pamplona, Spain
    Int Arch Allergy Immunol 136:58-72. 2005
    ..We assessed whether nonsteroidal anti-inflammatory drugs (NSAIDs) may provoke blood basophil activation in vitro in aspirin- and NSAID-hypersensitive patients, as detected by a flowcytometric technique using the CD63 marker--..
  29. ncbi Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis
    Emmanuel Bujold
    Department of Obstetrics and Gynecology, Faculty of Medicine, Laval University, Quebec, Canada
    Obstet Gynecol 116:402-14. 2010
    To estimate the effect of low-dose aspirin started in early pregnancy on the incidence of preeclampsia and intrauterine growth restriction (IUGR).
  30. pmc Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
    John Burn
    Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
    Lancet 378:2081-7. 2011
    Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint...
  31. ncbi Effects of low-dose aspirin on acute inflammatory responses in humans
    Thea Morris
    Division of Medicine, University College London, Centre for Clinical Pharmacology and Therapeutics, London, United Kingdom
    J Immunol 183:2089-96. 2009
    b>Aspirin is a unique nonsteroidal anti-inflammatory drug; at high doses (aspirin(high), 1g), it is anti-inflammatory stemming from the inhibition of cyclooxygenase and proinflammatory signaling pathways including NF-kappaB, but is ..
  32. doi Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 120:2577-85. 2009
    ..This is the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor using the PLATO (PLATelet inhibition and patient Outcomes) trial loading dose (180 mg) with a high loading dose (600 mg) of clopidogrel...
  33. ncbi Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
    Dominick J Angiolillo
    Division of Cardiology, University of Florida, Shands Jacksonville, 655 West 8th St, Jacksonville, FL 32209, USA
    Diabetes 54:2430-5. 2005
    To assess platelet function profiles in diabetic and nondiabetic patients on aspirin and clopidogrel therapy, two patient populations were included to investigate the 1) acute effects of a 300-mg clopidogrel loading dose (group 1, n = 52)..
  34. ncbi EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity
    E Nizankowska-Mogilnicka
    Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
    Allergy 62:1111-8. 2007
    b>Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most common causes of adverse drug reactions. Majority of them are of the hypersensitivity type...
  35. pmc Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis
    George Krasopoulos
    University Health Network, Division of Cardiovascular Surgery, Toronto General Hospital
    BMJ 336:195-8. 2008
    To determine if there is a relation between aspirin "resistance" and clinical outcomes in patients with cardiovascular disease.
  36. ncbi Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies
    Enrico Flossmann
    Stroke Prevention Research Unit, University Department of Clinical Neurology, Radcliffe Infirmary, Oxford OX2 6HE, UK
    Lancet 369:1603-13. 2007
    Randomised trials have shown that aspirin reduces the short-term risk of recurrent colorectal adenomas in patients with a history of adenomas or cancer, but large trials have shown no effect in primary prevention of colorectal cancer ..
  37. pmc Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome
    Hollis R O'Neal
    Department of Medicine, Section of Pulmonary and Critical Care Medicine, Louisiana State University Health Sciences Center, Baton Rouge, LA, USA
    Crit Care Med 39:1343-50. 2011
    ..We also investigated the effect of combined prehospital use of both statins and aspirin.
  38. ncbi Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
    Alessandra Larocca
    Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero Universitaria AOU S Giovanni Battista, Torino, Italy
    Blood 119:933-9; quiz 1093. 2012
    ..randomized substudy of a phase 3 trial compared the efficacy and safety of thromboprophylaxis with low-dose aspirin (ASA) or low-molecular-weight heparin (LMWH) in patients with newly diagnosed MM, treated with lenalidomide and ..
  39. ncbi Effect of aspirin and NSAIDs on risk and survival from colorectal cancer
    Farhat V N Din
    Colon Cancer Genetics Group and Academic Coloproctology, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU, UK
    Gut 59:1670-9. 2010
    Previous studies have shown that aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) lower colorectal cancer (CRC) risk. However, the lowest effective NSAID dose, treatment duration, and effects on survival are not defined...
  40. ncbi Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)
    Michael D Ezekowitz
    Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA, USA
    Am J Cardiol 100:1419-26. 2007
    ..to receive blinded doses of 50-, 150-, or 300-mg dabigatran twice daily alone or combined with 81- or 325-mg aspirin or open-label warfarin administered to achieve an international normalized ratio of 2 to 3 for 12 weeks...
  41. ncbi Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis
    Marc I Chimowitz
    Department of Neurology, School of Medicine, Emory University, Atlanta, USA
    N Engl J Med 352:1305-16. 2005
    Atherosclerotic intracranial arterial stenosis is an important cause of stroke. Warfarin is commonly used in preference to aspirin for this disorder, but these therapies have not been compared in a randomized trial.
  42. pmc Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)
    James M Scheiman
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Heart 97:797-802. 2011
    ....
  43. doi Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels
    Meiling Lu
    Cell Death Regulation Laboratory, Department of Medicine and Cell and Molecular Biology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Clin Cancer Res 14:3168-76. 2008
    ..We examined whether the nonsteroidal anti-inflammatory drug aspirin sensitized cancer cells to TRAIL agonists in vitro and in vivo and investigated the underlying mechanism.
  44. doi Effect of single nucleotide polymorphisms within the interleukin-4 promoter on aspirin intolerance in asthmatics and interleukin-4 promoter activity
    Byung Soo Kim
    Division of Molecular and Life Sciences, College of Science and Technology, Hanyang University, Sangrok Ku, Ansan, Gyeonggi Do, Korea
    Pharmacogenet Genomics 20:748-58. 2010
    b>Aspirin affects interleukin-4 (IL-4) synthesis; however, the genetic role of IL-4 has not been evaluated in asthmatics with aspirin hypersensitivity...
  45. ncbi Association of PTGER gene family polymorphisms with aspirin intolerant asthma in Korean asthmatics
    Byung Lae Park
    Department of Life Science, Sogang University, Seoul, Korea
    BMB Rep 43:445-9. 2010
    b>Aspirin-intolerant asthma (AIA) is characterized by severe asthmatic attack after ingestion of aspirin and/or non-steroidal anti-inflammatory drugs...
  46. ncbi The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome
    P Gamboa
    Allergy Unit, Hospital Basurto, Bilbao, Spain
    Clin Exp Allergy 34:1448-57. 2004
    ..Today, it is still claimed that no in vitro diagnostic tests exist for that condition and that the only way to confirm the diagnosis is a provocation challenge...
  47. doi Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial
    Joseph J Y Sung
    Institute of Digestive Disease, Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong
    Ann Intern Med 152:1-9. 2010
    It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin.
  48. ncbi Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis
    Patrick Andre
    Millennium Pharmaceuticals, Inc, 256 E Grand Ave, South San Francisco, Calif 9408, USA
    Circulation 108:2697-703. 2003
    ..This study was designed to determine whether (1) P2Y12 antagonism synergizes with other antithrombotics and (2) anticoagulants (thrombin inhibitors) affect the antithrombotic activity elicited by P2Y12 antagonism...
  49. ncbi Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases
    T E Van Dyke
    Department of Periodontology and Oral Biology, Boston University, Goldman School of Dental Medicine, 100 East Newton Street, Boston, MA 02118, USA
    J Dent Res 82:82-90. 2003
    ....
  50. pmc Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation
    N Chiang
    Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Exp Med 191:1197-208. 2000
    Lipoxin (LX) A(4) and aspirin-triggered LX (ATL) are endogenous lipids that regulate leukocyte trafficking via specific LXA(4) receptors (ALXRs) and mediate antiinflammation and resolution...
  51. ncbi Prasugrel versus clopidogrel in patients with acute coronary syndromes
    Stephen D Wiviott
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 357:2001-15. 2007
    Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention.
  52. ncbi Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1
    Sheng wei Jin
    Department of Anesthesiology, Second Affiliated Hospital, Wenzhou Medical College, Wenzhou, China
    Anesth Analg 104:369-77. 2007
    ..We hypothesized that posttreatment with 15-epi-16-parafluoro-phenoxy lipoxin A4 (ATL) could attenuate lipopolysaccharide (LPS)-induced acute lung injury in mice...
  53. ncbi Clinical and pathologic perspectives on aspirin sensitivity and asthma
    Donald D Stevenson
    Division of Allergy, Asthma and Immunology and the Department of Medicine, Scripps Clinic and the Scripps Research Institute, La Jolla, USA
    J Allergy Clin Immunol 118:773-86; quiz 787-8. 2006
    b>Aspirin and other nonsteroidal anti-inflammatory drugs that inhibit COX-1 induce unique nonallergic reactions, consisting of attacks of rhinitis and asthma...
  54. ncbi Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues
    Michael J Thun
    Department of Epidemiology and Surveillance Research, American Cancer Society, National Home Office, Atlanta, GA 30329 4251, USA
    J Natl Cancer Inst 94:252-66. 2002
    ..Finally, we suggest research opportunities that may help to accelerate the future clinical application of NSAIDs for cancer prevention or treatment...
  55. ncbi Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Hoffberger Bldg, Suite 56, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 115:3156-64. 2007
    The antiplatelet effect of aspirin is attributed to platelet cyclooxygenase-1 inhibition...
  56. ncbi Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data
    Lisa M Askie
    Centre for Perinatal Health Services Research, University of Sydney, Sydney, Australia
    Lancet 369:1791-8. 2007
    ..Antiplatelet agents, especially low-dose aspirin, might prevent or delay pre-eclampsia, and thereby improve outcome...
  57. doi Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
    Shamir R Mehta
    McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
    Lancet 376:1233-43. 2010
    Clopidogrel and aspirin are the most commonly used antiplatelet therapies for percutaneous coronary intervention (PCI)...
  58. pmc Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
    Ralph L Sacco
    Miller School of Medicine, University of Miami, Miami, USA
    N Engl J Med 359:1238-51. 2008
    Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel.
  59. ncbi Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent
    Fabiana S Machado
    Department of Immunology, Duke University Medical Center, Durham, North Carolina 27705, USA
    Nat Med 12:330-4. 2006
    Control of inflammation is crucial to prevent damage to the host during infection. Lipoxins and aspirin-triggered lipoxins are crucial modulators of proinflammatory responses; however, their intracellular mechanisms have not been ..
  60. ncbi Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin
    Steen Husted
    Department of Medicine and Cardiology, Arhus University Hospital, Denmark
    Eur Heart J 27:1038-47. 2006
    ..This double-blind, parallel-group study was conducted to assess the pharmacodynamics, pharmacokinetics, and safety of AZD6140, the first oral, reversible adenosine diphosphate (ADP) receptor antagonist...
  61. ncbi Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study
    J Hedman
    Department of Respiratory Medicine, Tampere University Hospital, Finland
    Int J Epidemiol 28:717-22. 1999
    ..The prevalence and relation to asthma of aspirin intolerance, nasal polyposis, allergic rhinitis and smoking habits were also examined.
  62. ncbi Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis
    Ana R Sousa
    Guy s, King s and St Thomas School of Medicine, London, United Kingdom
    N Engl J Med 347:1493-9. 2002
    Patients with asthma who have aspirin sensitivity have greater cysteinyl leukotriene production and greater airway hyperresponsiveness to the effects of inhaled cysteinyl leukotrienes than their aspirin-tolerant counterparts...
  63. doi Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial
    F Gerald R Fowkes
    Centre for Population Health Sciences, University of Edinburgh, Scotland
    JAMA 303:841-8. 2010
    ..Screening for a low ABI can identify an asymptomatic higher risk group potentially amenable to preventive treatments...
  64. doi A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
    Dominick J Angiolillo
    Division of Cardiology, University of Florida College of Medicine at Shands Jacksonville, Jacksonville, FL 32209, USA
    Eur Heart J 29:2202-11. 2008
    ..The aim of this pilot study was to assess the functional impact of cilostazol in T2DM patients on standard aspirin and clopidogrel treatment.
  65. ncbi Aspirin dose for the prevention of cardiovascular disease: a systematic review
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, Lexington, USA
    JAMA 297:2018-24. 2007
    More than 50 million US adults take aspirin regularly for long-term prevention of cardiovascular disease, typically either 81 mg/d or 325 mg/d. Controversy remains regarding the most appropriate long-term daily dose.
  66. ncbi Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin
    Brian F Gage
    Division of General Medical Sciences, Washington University School of Medicine Campus Box 8005, 660 S Euclid Ave, St Louis, MO 63110, USA
    Circulation 110:2287-92. 2004
    ..Although adjusted-dose warfarin is superior to aspirin for reducing stroke in AF, the absolute risk reduction of warfarin depends on the stroke rate with aspirin...
  67. doi A possible association of EMID2 polymorphisms with aspirin hypersensitivity in asthma
    Charisse Flerida A Pasaje
    Department of Life Science, Sogang University, 1 Shinsu dong, Mapo gu, Seoul, 121 742, Republic of Korea
    Immunogenetics 63:13-21. 2011
    b>Aspirin-intolerant asthma (AIA) is an asthma phenotype characterized by the development of bronchoconstriction following ingestion of aspirin...
  68. doi Prothrombotic and hemorrhagic effects of aspirin
    Omar Aguejouf
    Laboratoire d Hématologie Université Victor Segalen Bordeaux 2, Bordeaux, France
    Clin Appl Thromb Hemost 15:523-8. 2009
    b>Aspirin remains the most widely used drug for prevention of vascular events...
  69. ncbi Modulation of thiol homeostasis induced by H2S-releasing aspirin
    Daniela Giustarini
    Department of Evolutionary Biology, Laboratory of Pharmacology and Toxicology, University of Siena, Siena, Italy
    Free Radic Biol Med 48:1263-72. 2010
    The H(2)S-releasing aspirin (ACS14) containing a dithiolethione moiety has been demonstrated to maintain the thromboxane-suppressing activity of the parent compound, but it seems to spare the gastric mucosa by affecting redox imbalance ..
  70. ncbi Aspirin with or without an antiemetic for acute migraine headaches in adults
    Varo Kirthi
    Pain Research and Nuffield Department of Anaesthetics, University of Oxford, West Wing Level 6, John Radcliffe Hospital, Oxford, Oxfordshire, UK, OX3 9DU
    Cochrane Database Syst Rev 4:CD008041. 2010
    ..OBJECTIVES: To determine the efficacy and tolerability of aspirin, alone or in combination with an antiemetic, compared to placebo and other active interventions in the treatment ..
  71. doi Aspirin for preventing the recurrence of venous thromboembolism
    Cecilia Becattini
    Division of Internal and Cardiovascular Medicine and Stroke Unit, Department of Internal Medicine, University of Perugia, Perugia, Italy
    N Engl J Med 366:1959-67. 2012
    ..Extending anticoagulation prevents recurrences but is associated with increased bleeding. The benefit of aspirin for the prevention of recurrent venous thromboembolism is unknown.
  72. ncbi Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis
    Carl van Walraven
    Clinical Epidemiology Unit, Ottawa Health Research Institute, F 6, Ottawa Hospital, Civic Campus, 1053 Carling Ave, Ottawa, Ontario, Canada K1Y 4E9
    JAMA 288:2441-8. 2002
    ..Patients with nonvalvular atrial fibrillation (AF) have an increased risk of stroke and other vascular events...
  73. doi Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
    Marie Germaine Bousser
    Hopital Lariboisiere, INSERM U, Paris Diderot University, France
    Lancet 377:2013-22. 2011
    ..We compared the selective thromboxane-prostaglandin receptor antagonist terutroban with aspirin in the prevention of cerebral and cardiovascular ischaemic events in patients with a recent non-cardioembolic ..
  74. doi The role of aspirin in cancer prevention
    Michael J Thun
    Epidemiology Research Program, American Cancer Society, 250 Williams Street, Atlanta, GA 30303 1002, USA michael thun cancer org
    Nat Rev Clin Oncol 9:259-67. 2012
    Clinical guidelines for prophylactic aspirin use currently only consider the cardiovascular benefits of aspirin, weighed against the potential harm from aspirin-induced bleeding...
  75. doi Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis
    Stéphanie Roberge
    Department of Social and Preventive Medicine, Universite Laval, Quebec City, Que, Canada
    Fetal Diagn Ther 31:141-6. 2012
    To compare the effect of early administration of aspirin on the risk of preterm and term preeclampsia.
  76. pmc Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses
    Alexandre P Rogerio
    Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 189:1983-91. 2012
    ..In this study, we determined the impact of resolvin D1 (RvD1) and aspirin-triggered RvD1 (AT-RvD1) on the development of allergic airway responses and their resolution...
  77. ncbi Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial
    Reinhard Dengler
    Department of Neurology, Medizinische Hochschule Hannover, Hannover, Germany
    Lancet Neurol 9:159-66. 2010
    ..The EARLY trial aimed to compare outcome in patients given aspirin plus extended-release dipyridamole twice daily either within 24 h of stroke or TIA or after 7 days of aspirin ..
  78. doi Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction
    Fook Hong Ng
    Department of Medicine and Geriatric, Ruttonjee Hospital, Hong Kong, China
    Am J Gastroenterol 107:389-96. 2012
    ..in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics...
  79. pmc Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study
    Mette Charlot
    Department of Cardiology, Copenhagen University Hospital Gentofte, Post 635, Niels Andersens Vej 65, 2900 Hellerup, Denmark
    BMJ 342:d2690. 2011
    To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction.
  80. doi Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
    Antonio Palumbo
    University of Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, Torino, Italy
    J Clin Oncol 29:986-93. 2011
    ..In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism ..
  81. pmc NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts
    Karuppaiyah Selvendiran
    Davis Heart and Lung Research Institute and Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Cell Cycle 7:81-8. 2008
    We have previously reported the inhibitory effect of NCX-4016, a nitro derivative of aspirin, on the proliferation of cisplatin-resistant human ovarian cancer cells, in vitro (Bratasz et al., Proc Natl Acad Sci USA 2006; 103:3914-9)...
  82. doi Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis
    Tina L Pinto Slottow
    Division of Cardiology, Washington Hospital Center, Washington, District of Columbia, USA
    Am J Cardiol 104:525-30. 2009
    ..with a cohort of patients who had not would exhibit greater platelet reactivity and a greater prevalence of aspirin and clopidogrel resistance...
  83. pmc Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy
    A Biffi
    Department of Neurology and Hemorrhagic Stroke Research Program, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, 175 Cambridge Street, Suite 300, Boston, MA 02114, USA
    Neurology 75:693-8. 2010
    ..To identify and compare clinical and neuroimaging predictors of primary lobar intracerebral hemorrhage (ICH) recurrence, assessing their relative contributions to recurrent ICH...
  84. ncbi Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials
    Jeffrey S Berger
    Department of Cardiovascular Medicine, Duke University, Durham, NC, USA
    JAMA 295:306-13. 2006
    b>Aspirin therapy reduces the risk of cardiovascular disease in adults who are at increased risk. However, it is unclear if women derive the same benefit as men.
  85. ncbi Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial
    Hiroshi Sato
    Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan
    Stroke 37:447-51. 2006
    ..We examined the efficacy and safety of aspirin therapy in Japanese patients with NVAF in a prospective randomized multicenter trial.
  86. doi Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial
    Carl A Laskin
    University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, Canada
    J Rheumatol 36:279-87. 2009
    ..loss (RPL) and either autoantibodies or a coagulation abnormality, treated with low molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone, and to place our results in context with other randomized clinical trials (RCT) with ..
  87. pmc Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease
    G E Celik
    Ankara University School of Medicine, Division of Allergy, Ankara, Turkey
    Clin Exp Allergy 39:1522-31. 2009
    Basophil activation has been implicated in the pathogenesis of aspirin-exacerbated respiratory disease (AERD)...
  88. doi Association of SLC6A12 variants with aspirin-intolerant asthma in a Korean population
    Charisse Flerida A Pasaje
    Department of Life Science, Sogang University, Seoul, 121 742, Republic of Korea
    Ann Hum Genet 74:326-34. 2010
    b>Aspirin-intolerant asthma (AIA) occurs from asthma exacerbation after exposure to aspirin. However, the underlying mechanisms of AIA occurrence are still unclear...
  89. doi The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases
    Rohit K Katial
    Division of Allergy and Immunology, National Jewish Health, Denver, CO 80206, USA
    J Allergy Clin Immunol 126:738-44. 2010
    Patients with aspirin-exacerbated respiratory disease have been shown to benefit clinically from aspirin desensitization followed by chronic high-dose aspirin therapy. However, the mechanism of this phenomenon is still unclear.
  90. doi Duration of dual antiplatelet therapy after implantation of drug-eluting stents
    Seung Jung Park
    Department of Cardiology, Center for Medical Research and Information, University of Ulsan College of Medicine, Seoul, South Korea
    N Engl J Med 362:1374-82. 2010
    ..The potential benefits and risks of the use of dual antiplatelet therapy beyond a 12-month period in patients receiving drug-eluting stents have not been clearly established...
  91. pmc Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease
    Rehan Qayyum
    Division of General Internal Medicine, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Cardiol 101:1359-63. 2008
    Compared with men, women have greater platelet aggregation before and after low-dose aspirin. It is not known whether high-dose aspirin therapy brings residual platelet aggregation in women closer to that in men...
  92. ncbi Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents
    Anna Maria Gori
    Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy
    J Am Coll Cardiol 52:734-9. 2008
    This study sought to determine the incidence of aspirin nonresponsiveness in addition to clopidogrel nonresponsiveness and whether this association identifies patients at an increased risk of drug-eluting stent (DES) thrombosis.
  93. doi Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome
    David Tanne
    Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel
    Neurobiol Dis 30:56-64. 2008
    ..eAPS) or adjuvant (controls) and treated daily from 1 month after immunization with either sham injections, aspirin (1.2 mg/kg) or enoxaparin (1 mg/kg) for 3 months...
  94. doi Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease
    E L Grove
    Departments ofCardiology Clinical Biochemistry, Aarhus University Hospital, Skejby, Aarhus, Denmark
    J Thromb Haemost 9:185-91. 2011
    Previous studies have demonstrated considerable variation in the antiplatelet effect of aspirin.
  95. ncbi Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome
    John Burn
    Institute of Human Genetics, Newcastle University, International Centre for Life, Central Pkwy, Newcastle upon Tyne NE1 3BZ, United Kingdom
    N Engl J Med 359:2567-78. 2008
    Observational and epidemiologic data indicate that the use of aspirin reduces the risk of colorectal neoplasia; however, the effects of aspirin in the Lynch syndrome (hereditary nonpolyposis colon cancer) are not known...
  96. doi Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 105:445-52. 2010
    Despite its proven efficacy, low cost, and wide availability, aspirin remains underused. We examined current aspirin use and determined factors that influence its use among outpatients in the United States (US)...
  97. ncbi Effect of statin drugs and aspirin on progression in open-angle glaucoma suspects using confocal scanning laser ophthalmoscopy
    Dawn K De Castro
    Department of Ophthalmology, University of California at San Francisco, San Francisco, California 94143 0730, USA
    Clin Experiment Ophthalmol 35:506-13. 2007
    To determine the effect of statins and aspirin on the rate of progression of optic nerve parameters in open-angle glaucoma (OAG) suspects, as defined by confocal scanning laser ophthalmoscopy (CSLO).
  98. ncbi Aspirin induces gastric epithelial barrier dysfunction by activating p38 MAPK via claudin-7
    Tadayuki Oshima
    Department of Internal Medicine and Bioregulation, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Am J Physiol Cell Physiol 295:C800-6. 2008
    ..However, the mechanism by which aspirin affects the function of gastric epithelial tight junctions is unknown...
  99. doi First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies
    Udaya S Tantry
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circ Cardiovasc Genet 3:556-66. 2010
    ..The influence of cytochrome P450 (CYP) 2C19 genotype on platelet function in patients treated with ticagrelor versus clopidogrel is unknown...
  100. pmc Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes
    Levente Jozsef
    Research Center, Maisonneuve Rosemont Hospital and Department of Medicine, University of Montreal, Montreal, QC, Canada H1T 2M4
    Proc Natl Acad Sci U S A 99:13266-71. 2002
    Lipoxin A(4) (LXA(4)) and aspirin-triggered 15-epi-LXA(4) (ATL) are emerging as endogenous braking signals for neutrophil-mediated tissue injury...
  101. ncbi A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)
    Amar Rash
    Northern General Hospital, Medicine for the Elderly, Sheffield, UK
    Age Ageing 36:151-6. 2007
    ..Although trials demonstrate reductions in stroke with warfarin, audit data show that it is still underused. However, anti-coagulation in the very elderly is not without risk...

Research Grants82

  1. Novel mechanisms by which aspirin might protect against atherosclerosis
    Sampath Parthasarathy; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Aspirin ('acetylsalicylic acid') inhibits the formation of prostaglandins (PGs) that cause inflammation, swelling, pain and fever...
  2. Novel mechanisms by which aspirin might protect against atherosclerosis
    Sampath Parthasarathy; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Aspirin ('acetylsalicylic acid') inhibits the formation of prostaglandins (PGs) that cause inflammation, swelling, pain and fever...
  3. PREVENTION OF ULCER HEMORRHAGE BY H PYLORI ERADICATION
    Dennis Jensen; Fiscal Year: 2000
    ..pylori eradication plus full-dose H2RA maintenance in preventing recurrent ulcer hemorrhage and 2) ingestion of aspirin (ASA) or other non-steroidal anti-inflammatory drugs (NSAIDs) or recurrence of H...
  4. PREVENTION OF ULCER HEMORRHAGE BY H PYLORI ERADICATION
    Dennis Jensen; Fiscal Year: 1999
    ..pylori eradication plus full-dose H2RA maintenance in preventing recurrent ulcer hemorrhage and 2) ingestion of aspirin (ASA) or other non-steroidal anti-inflammatory drugs (NSAIDs) or recurrence of H...
  5. Low-dose Aspirin and Human Skin Blood Flow
    Lacy A Holowatz; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Daily low-dose aspirin (81 mg) therapy is the gold standard for primary and secondary prevention of atherothrombotic disease...
  6. ASPIRIN DESENSITIZATION IN HYPERPLASTIC SINUSITIS
    Larry Borish; Fiscal Year: 2000
    b>Aspirin sensitive patients with asthma often experience continuous inflammation of their nasal and sinus tissues, which is complicated by repeated sinus infections (chronic sinusitis)...
  7. Who benefits from Colorectal Cancer Screening? A subgroup Analysis of the Minnes
    Aasma Shaukat; Fiscal Year: 2009
    ..Additionally, the effects of other baseline variables, such as co-morbidities and intake of aspirin on outcomes have not been reported...
  8. RISK SCORE FOR CORONARY ANEURYSMS IN KAWASAKI SYNDROME
    Jane Newburger; Fiscal Year: 1992
    ..Treatment with intravenous gamma globulin and aspirin with the first 10 days of illness has been demonstrated to reduce the prevalence of coronary lesions...
  9. IN VIVO INHIBITORS OF OCULAR PROSTAGLANDIN SYNTHESIS
    STEVEN PODOS; Fiscal Year: 1980
    The synthesis of prostaglandins occurs in the eye. Aspirin-like compounds inhibit prostaglandin synthesis. A differential sensitivity of the prostaglandin synthetase system exists in different tissues...
  10. ASPIRIN, MUCOSAL PROSTAGLANDINS, AND COLON PROLIFERATION
    Gordon Luk; Fiscal Year: 1993
    This pilot intervention study is designed to determine whether aspirin (ASA) can normalize the colorectal mucosa] hyperproliferation found in patients with adenomatous polyps...
  11. A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
    Steven Kawut; Fiscal Year: 2007
    ..unreadable] [unreadable] HMG-CoA reductase inhibitors (statins) and aspirin are very safe, highly-effective cardiovascular therapies used by millions of people...
  12. Aspirin and Simvastatin--Pulmonary Arterial Hypertension
    Steven Kawut; Fiscal Year: 2006
    ..unreadable] [unreadable] HMG-CoA reductase inhibitors (statins) and aspirin are very safe, highly-effective cardiovascular therapies used by millions of people...
  13. G I MUCOSAL BARRIER IN HEALTH AND SURGICAL DISEASE
    William Silen; Fiscal Year: 1992
    ..of acid secretion, and by physiologic conditions which predispose to ulceration? 2) Do injurious agents such as aspirin (ASA), salicylate (SA), other non- steroidal anti-inflammatory agents, and drugs such as prostaglandins on growth ..
  14. A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
    Steven Kawut; Fiscal Year: 2009
    ..HMG-CoA reductase inhibitors (statins) and aspirin are very safe, highly-effective cardiovascular therapies used by millions of people...
  15. A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
    Steven Kawut; Fiscal Year: 2009
    ..HMG-CoA reductase inhibitors (statins) and aspirin are very safe, highly-effective cardiovascular therapies used by millions of people...
  16. Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
    Genhong Cheng; Fiscal Year: 2009
    ..metabolic diseases such as Reye's Syndrome, a hepatotoxicity disease that occurs when children are given aspirin in the context of a viral infection, or acetaminophen (APAP)-induced hepatotoxicity, which accounts for about ..
  17. Active site amino acids of cAMP phosphodiesterase 3A
    Robert Colman; Fiscal Year: 2000
    ..Currently, the two anti-platelet agents with proven efficacy are aspirin, which inhibits cyclooxygenase-dependent synthesis of thromboxane A2 )TXA2), and clopidogrel or ticlopidine, ..
  18. Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
    Genhong Cheng; Fiscal Year: 2010
    ..metabolic diseases such as Reye's Syndrome, a hepatotoxicity disease that occurs when children are given aspirin in the context of a viral infection, or acetaminophen (APAP)-induced hepatotoxicity, which accounts for about ..
  19. ANTIOXIDANT MODULATION OF FREE RADICAL GENERATION IN CIRRHOSIS
    EMMA MEAGHER; Fiscal Year: 1999
    ..of hepatic injury and that while the enzymatically produced metabolite of thromboxane A2 is reduced by aspirin administration there is no alteration in isoprostane excretion...
  20. GI safety and therapeutics of oil-based PC-NSAIDs
    Lenard Lichtenberger; Fiscal Year: 2004
    ..modifying the formulae of PC-NSAIDs from an aqueous suspension to an oil-based formulation containing the NSAID (aspirin or ibuprofen) and equal parts of triple strength lecithin, which has benefits with regards to drug stability, ..
  21. GI safety and therapeutics of oil-based PC-NSAIDs
    Lenard Lichtenberger; Fiscal Year: 2005
    ..modifying the formulae of PC-NSAIDs from an aqueous suspension to an oil-based formulation containing the NSAID (aspirin or ibuprofen) and equal parts of triple strength lecithin, which has benefits with regards to drug stability, ..
  22. The Effects of Fish Oil and Aspirin on Cardiovascular Risk in Type 2 Diabetes
    ROBERT CHARLES BLOCK; Fiscal Year: 2010
    ..The potential benefits of combining inexpensive over-the- counter aspirin and fish oil-derived omega-3 fatty acids (eicosapentaenoic acid {EPA} and docosahexaenoic acid {DHA};"EPA+DHA") ..
  23. Role of Neutrophil-Platelet Interactions in Vascular Occlusive Disorders
    Nauder Faraday; Fiscal Year: 2009
    ..Antiplatelet therapy with aspirin, clopidogrel, or their combination, is currently standard of care for prevention of myocardial infarction (MI), ..
  24. Role of Neutrophil-Platelet Interactions in Vascular Occlusive Disorders
    Nauder Faraday; Fiscal Year: 2010
    ..Antiplatelet therapy with aspirin, clopidogrel, or their combination, is currently standard of care for prevention of myocardial infarction (MI), ..
  25. Gender Selectivity to Colon Cancer Chemoprevention by NSAIDS
    RAMESH K contact WALI; Fiscal Year: 2010
    ..ulcers, GI bleeding, hemorrhagic strokes etc, thereby cautioning that the risks may outweigh the benefits of aspirin and NSAIDS in preventing CRC for average risk use...
  26. Gender Selectivity to Colon Cancer Chemoprevention by NSAIDS
    Ramesh Wali; Fiscal Year: 2009
    ..ulcers, GI bleeding, hemorrhagic strokes etc, thereby cautioning that the risks may outweigh the benefits of aspirin and NSAIDS in preventing CRC for average risk use...
  27. MOLECULAR MECHANISMS OF ASPIRIN IN CANCER PREVENTION
    Zigang Dong; Fiscal Year: 2000
    b>Aspirin is one of the most promising agents for the chemoprevention of human cancer. The clinical usefulness of aspirin is partially limited by its side effects...
  28. MOLECULAR MECHANISMS OF ASPIRIN IN CANCER PREVENTION
    Zigang Dong; Fiscal Year: 1999
    b>Aspirin is one of the most promising agents for the chemoprevention of human cancer. The clinical usefulness of aspirin is partially limited by its side effects...
  29. MOLECULAR MECHANISMS OF ASPIRIN IN CANCER PREVENTION
    Zigang Dong; Fiscal Year: 2001
    b>Aspirin is one of the most promising agents for the chemoprevention of human cancer. The clinical usefulness of aspirin is partially limited by its side effects...
  30. Aspirin, Helicobacter Pylori, and Peptic Ulcer Disease
    Edward Lew; Fiscal Year: 2003
    b>Aspirin and other non-steroidal anti-inflammatory drugs are widely used to treat pain and inflammation, and at low doses, aspirin is also increasingly being used for cardiovascular prophylaxis...
  31. Aspirin, Helicobacter Pylori, and Peptic Ulcer Disease
    Edward Lew; Fiscal Year: 2002
    b>Aspirin and other non-steroidal anti-inflammatory drugs are widely used to treat pain and inflammation, and at low doses, aspirin is also increasingly being used for cardiovascular prophylaxis...
  32. ACID NEUTRALIZATION AND DISPOSAL IN GASTRIC EPITHELIUM
    David Soybel; Fiscal Year: 1992
    ..on cotransport or exchange mechanisms with Na+, K+ or C1-; and 3) that topical agents of injury such as aspirin or bile salts may not only reduce the resistance of the epithelium to back-diffusion of acid, but they may ..
  33. RANDOMIZED TRIALS OF VITAMIN SUPPLEMENTS AND EYE DISEASE
    William Christen; Fiscal Year: 2002
    ..The PHS is a randomized, double-blind, placebo-controlled trial of aspirin use in reducing cardiovascular disease, and beta-carotene in reducing cancer, among 22,071 male U.S...
  34. RANDOMIZED TRIALS OF VITAMIN SUPPLEMENTS AND EYE DISEASE
    William Christen; Fiscal Year: 2000
    ..The PHS is a randomized, double-blind, placebo-controlled trial of aspirin use in reducing cardiovascular disease, and beta-carotene in reducing cancer, among 22,071 male U.S...
  35. RANDOMIZED TRIALS OF VITAMIN SUPPLEMENTS AND EYE DISEASE
    William Christen; Fiscal Year: 2001
    ..The PHS is a randomized, double-blind, placebo-controlled trial of aspirin use in reducing cardiovascular disease, and beta-carotene in reducing cancer, among 22,071 male U.S...
  36. RANDOMIZED TRIALS OF VITAMIN SUPPLEMENTS AND EYE DISEASE
    William Christen; Fiscal Year: 1999
    ..The PHS is a randomized, double-blind, placebo-controlled trial of aspirin use in reducing cardiovascular disease, and beta-carotene in reducing cancer, among 22,071 male U.S...
  37. RANDOMIZED TRIALS OF VITAMIN SUPPLEMENTS AND EYE DISEASE
    William Christen; Fiscal Year: 1993
    ..The PHS is a randomized, double-blind, placebo-controlled trial of aspirin use in reducing cardiovascular disease, and beta-carotene in reducing cancer, among 22,071 male U.S...
  38. POLYMORPHISMS IN PG/COX PATHWAY AND COLORECTAL POLYPS
    Cornelia Ulrich; Fiscal Year: 2003
    b>Aspirin and other non-steroidal inflammatory drugs (NSAIDs) reduce the recurrence of colorectal polyps among patients with familial adenomatous polyposis (FAP) and are associated with a lower risk of both adenoma and colorectal cancer...
  39. POLYMORPHISMS IN PG/COX PATHWAY AND COLORECTAL POLYPS
    Cornelia Ulrich; Fiscal Year: 2001
    b>Aspirin and other non-steroidal inflammatory drugs (NSAIDs) reduce the recurrence of colorectal polyps among patients with familial adenomatous polyposis (FAP) and are associated with a lower risk of both adenoma and colorectal cancer...
  40. POLYMORPHISMS IN PG/COX PATHWAY AND COLORECTAL POLYPS
    Cornelia Ulrich; Fiscal Year: 2002
    b>Aspirin and other non-steroidal inflammatory drugs (NSAIDs) reduce the recurrence of colorectal polyps among patients with familial adenomatous polyposis (FAP) and are associated with a lower risk of both adenoma and colorectal cancer...
  41. GENE-ENVIRONMENT EFFECTS AND COLON ADENOMAS
    Henry Lin; Fiscal Year: 2000
    ..Environmental exposures to be analyzed include: meat, cruciferous vegetables, and aspirin. High meat diets are believed to be risk factors, whereas cruciferous vegetables and aspirin are believed to be ..
  42. GENE-ENVIRONMENT EFFECTS AND COLON ADENOMAS
    Henry Lin; Fiscal Year: 1999
    ..Environmental exposures to be analyzed include: meat, cruciferous vegetables, and aspirin. High meat diets are believed to be risk factors, whereas cruciferous vegetables and aspirin are believed to be ..
  43. ASYMPTOMATIC CAROTID ARTERY STENOSIS COLLABORATIVE STUDY
    James Toole; Fiscal Year: 1990
    ..Surgical. The major aim of the surgical component is to compare the effectiveness of aspirin + endarterectomy versus aspirin alone in reducing the incidence of TIA and cerebral infarction in patients with ..
  44. ASPirin in Reducing Events in the Elderly
    Richard Grimm; Fiscal Year: 2009
    This Application seeks funding for a randomized double-blind placebo-controlled trial of aspirin in primary prevention in healthy elderly people aged 70 years and over...
  45. TRIAL OF ASPIRIN AND VITAMIN E IN WOMEN
    Julie Buring; Fiscal Year: 1999
    ..an ongoing randomized, double-blind, placebo-controlled trial evaluating the benefits and risks of low-dose aspirin (100 mg on alternate days), vitamin E (600 IU on alternate days), and beta-carotene (50 mg on alternate days) ina ..
  46. PROSTACYCLIN AND ASPIRIN IN CORONARY PHARMACOLOGY
    NORINE CAPURRO; Fiscal Year: 1980
    ..Some dogs will be pretreated with aspirin. Prostacyclin levels in coronary sinus blood samples will be determined by radioimmunoassay for 6-..
  47. TRIAL OF ASPIRIN AND VITAMIN E IN WOMEN
    Julie Buring; Fiscal Year: 2000
    ..an ongoing randomized, double-blind, placebo-controlled trial evaluating the benefits and risks of low-dose aspirin (100 mg on alternate days), vitamin E (600 IU on alternate days), and beta-carotene (50 mg on alternate days) ina ..
  48. MECHANISMS OF AIRWAY INFLAMMATION IN ASPIRIN INTOLERANT ASTHMA
    ESTHER LANGMACK; Fiscal Year: 1999
    b>Aspirin-intolerant asthma is a clinical syndrome affecting 5-10% of the asthmatic population...
  49. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2003
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  50. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2001
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  51. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2002
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  52. Analgesic Use and Kidney Cancer
    Eunyoung Cho; Fiscal Year: 2009
    ..The NSAID aspirin is one of the most commonly used drugs in the U.S...
  53. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2002
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  54. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2002
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  55. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2003
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  56. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2003
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  57. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2002
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  58. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2005
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  59. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2005
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  60. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2004
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  61. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2004
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  62. NO Releasing Aspirin and Colon Cancer Chemoprevention
    Basil Rigas; Fiscal Year: 2004
    ..Current evidence suggests that they are much safer than traditional NSAIDs. Early studies indicate that an NO-aspirin (NO-ASA) derivative is much more effective than ASA in cultured cells and against colon preneoplastic lesions...
  63. ANALGESIC USE AND THE RISK OF CHRONIC RENAL FAILURE
    Gary Curhan; Fiscal Year: 2001
    ..with consumption of large amounts of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) but not aspirin. Since these analgesics are widely available and used, their association with renal dysfunction is particularly ..
  64. ANALGESIC USE AND THE RISK OF CHRONIC RENAL FAILURE
    Gary Curhan; Fiscal Year: 2000
    ..with consumption of large amounts of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) but not aspirin. Since these analgesics are widely available and used, their association with renal dysfunction is particularly ..
  65. ANALGESIC USE AND THE RISK OF CHRONIC RENAL FAILURE
    Gary Curhan; Fiscal Year: 2002
    ..with consumption of large amounts of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) but not aspirin. Since these analgesics are widely available and used, their association with renal dysfunction is particularly ..
  66. ANALGESIC USE AND THE RISK OF CHRONIC RENAL FAILURE
    Gary Curhan; Fiscal Year: 1999
    ..with consumption of large amounts of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) but not aspirin. Since these analgesics are widely available and used, their association with renal dysfunction is particularly ..
  67. ANALGESIC USE AND THE RISK OF CHRONIC RENAL FAILURE
    Gary Curhan; Fiscal Year: 2000
    ..with consumption of large amounts of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) but not aspirin. Since these analgesics are widely available and used, their association with renal dysfunction is particularly ..
  68. Lipidomic and Transcriptome Signatures in Aspirin-Exacerbated Respiratory Disease
    Joshua A Boyce; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Aspirin-exacerbated respiratory disease (AERD) is characterized by persistent chronic inflammation of the upper and lower airways leading to chronic rhinosinusitis, nasal polyposis, and asthma...
  69. THE PHARMACOLOGY OF ASPIRIN
    John Oates; Fiscal Year: 2006
    Acting as an antiplatelet drug, aspirin substantially reduces the occurrence of myocardial infarction and stroke...
  70. Pharmacogenomics of Anti-platelet Agents for CVD Prevent
    ALAN SHULDINER; Fiscal Year: 2005
    ..modes for primary and secondary prevention of coronary events is the use of anti-platelet agents, typically aspirin and clopidogrel (Plavix), which have been shown to decrease MI incidence rates by approximately 20-25%...
  71. Lipidomic and Transcriptome Signatures in Aspirin-Exacerbated Respiratory Disease
    Joshua Boyce; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Aspirin-exacerbated respiratory disease (AERD) is characterized by persistent chronic inflammation of the upper and lower airways leading to chronic rhinosinusitis, nasal polyposis, and asthma...
  72. ALCOHOL-INDUCED BEHAVIORAL TERATOGENESIS
    Edward Riley; Fiscal Year: 1990
    ..for this hypothesis stems from studies showing that pretreatment with the prostaglandin synthetase inhibitors, aspirin and indomethacin, prior to alcohol exposure reduces fetal hypoplasia and the incidence of fetal death and ..
  73. RESEARCH CENTER FOR PHARMACOLOGY AND DRUG TOXICOLOGY
    John Oates; Fiscal Year: 1993
    ..The molecular basis for the exquisite sensitivity of the release of PGD2 by niacin to very low doses of aspirin will be investigated, together with the regulation by prednisone of the cellular capacity for niacin-induced ..
  74. ALCOHOL-INDUCED BEHAVIORAL TERATOGENESIS
    Edward Riley; Fiscal Year: 1992
    ..for this hypothesis stems from studies showing that pretreatment with the prostaglandin synthetase inhibitors, aspirin and indomethacin, prior to alcohol exposure reduces fetal hypoplasia and the incidence of fetal death and ..